DR
David Malcom Rodman (Chief Medical Officer) filed 10 Form 4 reports in the trailing twelve months (0 purchases, 10 sales), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $9.3M of MLYS (262,752 sh across 3 lots, as filed), executed Jan 2. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
10
0 buys · 10 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$13.2M
shares × price, as filed
Last traded
Jul 15
Filed Jul 15
Median ADV $38.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $15.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
10 filings
Sector per market data · by filing · past 12 months
Most traded names
MLYS
Mineralys Therapeutics, Inc.
MLYS · 0 buys · 19 sells
19 filings
Recent filings
MLYSSALE
Mineralys Therapeutics, Inc.
View filing →
$205K6,348 sh × $32.32
Exec Jan 12
Filed Jan 13 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $9.3M
262,752 sh across 3 lots
Exec Jan 2
Filed Jan 6 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $446K
10,369 sh × $43.01
Exec Oct 15 2025
Filed Oct 15 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $334K
9,302 sh × $35.90
Exec Sep 15 2025
Filed Sep 16 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $147K
11,365 sh × $12.93
Exec Aug 13 2025
Filed Aug 14 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $166K
11,366 sh × $14.59
Exec Jul 14 2025
Filed Jul 15 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $166K
11,366 sh × $14.60
Exec Jun 13 2025
Filed Jun 16 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $174K
11,366 sh × $15.29
Exec May 14 2025
Filed May 15 2025 · 5:30 PM ET More filings →